Physician profile
Wafaa Foad
NPI 1093775108
$275.26
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $14.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $49.52 | 2019 | |
| Lilly USA, LLC | $46.01 | 2019 | |
| Janssen Biotech, INC. | $42.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.20 | 2019 | |
| Merz North America, INC. | $18.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.51 | 2019 | |
| Amgen INC. | $14.12 | 2020 | |
| Abbvie INC. | $14.07 | 2019 | |
| Glaxosmithkline, LLC. | $13.56 | 2019 | |
| Ucb, INC. | $13.48 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wafaa Foad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.